PYC vs. ONC, IXI, TCF, SNG, EVG, MTFB, ROQ, DEST, BSFA, and RENE
Should you be buying Physiomics stock or one of its competitors? The main competitors of Physiomics include Oncimmune (ONC), IXICO (IXI), Theracryf (TCF), Synairgen (SNG), Evgen Pharma (EVG), Motif Bio (MTFB), Roquefort Therapeutics (ROQ), Destiny Pharma (DEST), BSF Enterprise (BSFA), and ReNeuron Group (RENE). These companies are all part of the "biotechnology" industry.
Physiomics vs.
Physiomics (LON:PYC) and Oncimmune (LON:ONC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership, earnings and community ranking.
Oncimmune has a net margin of 581.63% compared to Physiomics' net margin of -106.80%. Physiomics' return on equity of -127.68% beat Oncimmune's return on equity.
25.0% of Oncimmune shares are owned by institutional investors. 4.2% of Physiomics shares are owned by company insiders. Comparatively, 31.0% of Oncimmune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Physiomics received 12 more outperform votes than Oncimmune when rated by MarketBeat users. However, 59.13% of users gave Oncimmune an outperform vote while only 55.56% of users gave Physiomics an outperform vote.
Physiomics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, Oncimmune has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.
Oncimmune has higher revenue and earnings than Physiomics. Physiomics is trading at a lower price-to-earnings ratio than Oncimmune, indicating that it is currently the more affordable of the two stocks.
In the previous week, Oncimmune had 1 more articles in the media than Physiomics. MarketBeat recorded 1 mentions for Oncimmune and 0 mentions for Physiomics. Physiomics' average media sentiment score of 0.00 beat Oncimmune's score of -0.45 indicating that Physiomics is being referred to more favorably in the media.
Summary
Oncimmune beats Physiomics on 11 of the 15 factors compared between the two stocks.
Get Physiomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Physiomics Competitors List
Related Companies and Tools
This page (LON:PYC) was last updated on 2/22/2025 by MarketBeat.com Staff
Free PYC Stock Alerts